These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 21269744)
21. The role of stem-cell transplantation in chronic lymphocytic leukemia risk-adapted therapy. Giné E; Moreno C; Esteve J; Montserrat E Best Pract Res Clin Haematol; 2007 Sep; 20(3):529-43. PubMed ID: 17707838 [TBL] [Abstract][Full Text] [Related]
22. The effect of allogeneic stem cell transplantation on high risk chronic lymphocytic leukaemia: a single centre retrospective analysis. Válková V; Schwarz J; Vítek A; Marková M; Pohlreich D; Benešová K; Michalová K; Cetkovský P; Trněný M Hematol Oncol; 2011 Mar; 29(1):22-30. PubMed ID: 20535783 [TBL] [Abstract][Full Text] [Related]
23. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. Pfitzner T; Reiser M; Barth S; Borchmann P; Schulz H; Schinköthe T; Oberhäuser F; Wessels J; Tur M; Diehl V; Engert A Ann Hematol; 2002 May; 81(5):258-66. PubMed ID: 12029535 [TBL] [Abstract][Full Text] [Related]
24. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR. Raponi S; Della Starza I; De Propris MS; Del Giudice I; Mauro FR; Marinelli M; Di Maio V; Piciocchi A; Foà R; Guarini A Br J Haematol; 2014 Aug; 166(3):360-8. PubMed ID: 24735016 [TBL] [Abstract][Full Text] [Related]
25. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. Mehta J; Powles R; Singhal S; Iveson T; Treleaven J; Catovsky D Bone Marrow Transplant; 1996 Mar; 17(3):371-5. PubMed ID: 8704689 [TBL] [Abstract][Full Text] [Related]
26. Clinical relevance of MRD in children undergoing allogeneic stem cell transplantation for ALL. Goulden N; Steward C Best Pract Res Clin Haematol; 2002 Mar; 15(1):59-70. PubMed ID: 11987916 [TBL] [Abstract][Full Text] [Related]
27. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. Díez-Campelo M; Pérez-Simón JA; Pérez J; Alcoceba M; Richtmon J; Vidriales B; San Miguel J Am J Hematol; 2009 Mar; 84(3):149-52. PubMed ID: 19123459 [TBL] [Abstract][Full Text] [Related]
28. Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells? Schilham MW; Balduzzi A; Bader P; Bone Marrow Transplant; 2005 Mar; 35 Suppl 1():S49-52. PubMed ID: 15812531 [TBL] [Abstract][Full Text] [Related]
29. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058 [TBL] [Abstract][Full Text] [Related]